Changes to clinical trials (amendments)

	Substantial amendments *	Notifications	Non-substantial amendments**
To be submitted to NoMA	Yes	Yes	No
Fee	5,160 NOK		
CHANGES TO THE PROTOCOL			
Change of main objective of the clinical trial	x		
Change of primary or secondary endpoint which is likely to have a significant impact on the safety or scientific value of the clinical trial	x		
Use of a new measurement for the primary endpoint(s)	x		
New toxicological or pharmacological data or new interpretation of toxicological or pharmacological data which is likely to impact on the risk/benefit assessment	x		
A change in the definition of the end of the trial, even if the trial has in practice already ended	x		
Addition of a treatment arm or placebo group	x		
Change of inclusion or exclusion criteria	x		
Changes in the number of patient visits during the course of the study	x		
Change of a diagnostic or medical monitoring procedure which is likely to have a significant impact on the safety or scientific value of the clinical trial	x		
Withdrawal of an independent Data Safety Monitoring Committee	x		
Change of IMP(s)	x		
Change of dosing of IMP(s)	x		
Change of mode of administration of IMP(s)	x		
Changes to the study design which is likely to have a significant impact on primary or major secondary statistical analysis or the risk/benefit assessment.	x		
Changes due to acute issues with patient safety. NoMA will respond but the change can be implemented immediately.	x		
Changes to the identification of the trial (e.g. change of title, etc.)			x
The addition/deletion of exploratory/tertiary endpoints			x
A minor increase in the duration of the trial (< 10 % of the overall time of the trial);			x
An increase in duration of > 10 % of the overall time of the trial, provided that: • the exposure to treatment with the IMP is not extended, • the definition of the end of the trial is unchanged, and • monitoring arrangements are unchanged			x
A change in the number of clinical trial participants per trial site, if the total number of participants in the Member State concerned is identical or the increase/ decrease is insignificant in view of the absolute number of participants			x
A change in the number of clinical trial participants in the Member State concerned, if the total number of participants is identical or the increase/decrease is insignificant in view of the absolute number of participants			x
A change in the documentation used by the research team for recording study data (e.g. case report form or data collection form)			x
Additional safety monitoring which is not part of an urgent safety measure but is taken on a precautionary basis			x

Changes to clinical trials (amendments)

Minor clarifications to the protocol			x
Correction of typographical errors			x
CHANGES TO THE PATIENT INFORMATION SHEET / CONSENT FORM			
Changes to the patient information sheet / consent form			x
CHANGES TO THE CONDUCT / MANAGEMENT OF THE CLINICAL TRIAL			
A change of sponsor or the sponsor's legal representative.	x		
The revocation or suspension of the IMP's marketing authorisation.	x		
A change of the contact person or in the contact details of the contact person (e.g. a change of e-mail or postal address). NoMA must be informed of this in order to execute its function as a Competent Authority.		x	
Change of National Coordinating Investigator		x	
Any change of person(s) other than the Sponsor or their legal representative, for example - the applicant, Clinical Research Associates (CRAs) who monitor the clinical trial for the Investigator, and Clinical Research Organisations (CROs)			x
Changes to the internal organisation of the sponsor or of the person(s) to whom certain tasks have been delegated			x
Changes in the logistical arrangements for storing/ transporting samples			x
Change of technical equipment			x
Addition or deletion per se of another Member State or Third Country concerned.			x
Addition / removal of a site in Norway			x
Changes concerning financial issues			x
CHANGES TO THE IMPD			
In regard to changes in the IMP(s) pharmaceutical, chemical or biological quality: some changes can be defined as substantial, whereas others non-substantial. For further guidance, please see Chapter 9 of the Guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials.	x	x	
CHANGES TO THE INVESTIGATOR'S BROCHURE (IB)			
New toxicological or pharmacological data or new interpretation of toxicological or pharmacological data of relevance for the investigator	x		
Changes to the Reference Safety Information (RSI) for the Annual Safety Report.	x		
An update of the IB that can change the initial risk/benefit assessment of the study or the safety profile of the IMPs.	x		
An update of the IB that does not change the initial risk/benefit assessment of the study or the safety profile of the IMP(s).		x	
DSURs, SUSARs, Annual Reports and End of Trial notifications (both local and global) must be submitted at the given deadlines		Will only be answered if NoMA finds it necessary to initiate actions due to safety issues.	

***** Examples of substantial amendments should serve as guidance for the case-by-case decision of the sponsor.
****** The sponsor does not have to notify non-substantial amendments to NoMA. However, non-substantial amendments should be recorded and contained in the documentation when it is subsequently submitted, for example in the subsequent

notification of a substantial amendment. Documentation of non-substantial amendments should also be available on request for inspection at the trial site or the sponsor premises as appropriate.